Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in...
The purpose of this study was to explore the association between race and socioeconomic status (SES) on health disparities in paediatric eyecare, to characterise the...
This paper describes the use of slab-off prisms for the treatment of vertical diplopia in the reading position. The following data were collected: main symptom...
The authors present a case control study of 41 adolescents (age 12-14) with myopia and 39 age- and sex-matched non-myopic controls. The myopic patients were...
This review article summarises the update on non-infectious retinal vasculitis (RV). It is primarily classified based on the type of retinal vessels involved and further...
In this retrospective cohort study, 288 eyes of 273 patients (mean ±SD age: 68.56 ±10.47 y; 32.60% females) with primary glaucoma who underwent trabeculectomy /...
This study sought to review the seasonality and the occurrence of Lyme disease within their institution with a focus on neuro-ophthalmic consequences. This was a...
In this study, the quality, reliability, technical quality and readability of online information related to childhood glaucoma was assessed. This was a cross-sectional study of...
Myopic traction maculopathy (MTM) is a sight-threatening complication of high myopia including macular retinoschisis (MRS) or foveoschisis, foveal detachment (FD) and myopic macular hole (MMH)....
Revolutionary eye treatments offer hope for children facing blindness from CLN2 batten disease. Robert Henderson discusses this, and his use of Heidelberg Engineering’s Spectralis device...
The aim is to present a case of neurofibromatosis type-1 (NF-1), also known as von Recklinghausen disease, who presented with bilateral multiple choroidal nodular nevi...
For the upcoming Eye News Dec/Jan 2025, our co-editor, David Lockington, had the opportunity to sit down with the CEO of IAPB, Peter Holland. We’re...